The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! The stock increased 8.08% or $0.34 on November 23, hitting $4.55. About 4.98 million shares traded hands or 104.10% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 50.00% since April 22, 2016 and is downtrending. It has underperformed by 55.41% the S&P500.
The move comes after 6 months positive chart setup for the $640.19M company. It was reported on Nov, 24 by Barchart.com. We have $4.87 PT which if reached, will make NASDAQ:ACHN worth $44.81 million more.
Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on February, 23. They expect $-0.17 earnings per share, down 241.67% or $0.29 from last year’s $0.12 per share. After $-0.15 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.33% negative EPS growth.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage
Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $16 is the highest target while $4 is the lowest. The $9.83 average target is 116.04% above today’s ($4.55) stock price. Achillion Pharma has been the topic of 15 analyst reports since August 13, 2015 according to StockzIntelligence Inc. On Friday, September 23 the stock rating was initiated by Wedbush with “Outperform”. UBS upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Tuesday, September 8 to “Buy” rating. Leerink Swann maintained it with “Market Perform” rating and $9 target price in Wednesday, May 4 report. The rating was upgraded by Robert W. Baird on Friday, February 26 to “Outperform”. The company was initiated on Wednesday, September 9 by Jefferies. The rating was maintained by Chardan Capital Markets on Friday, September 23 with “Sell”. Maxim Group maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Thursday, February 25. Maxim Group has “Buy” rating and $8 price target. Chardan Capital Markets initiated the stock with “Sell” rating in Thursday, July 14 report. The rating was downgraded by Leerink Swann on Friday, January 29 to “Market Perform”. The rating was maintained by Maxim Group on Thursday, August 13 with “Buy”.
According to Zacks Investment Research, “ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.”
Insitutional Activity: The institutional sentiment increased to 1.52 in 2016 Q2. Its up 0.52, from 1 in 2016Q1. The ratio is positive, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
The New York-based Baker Bros Advisors Lp has invested 0.2% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Turner Investments Lp last reported 2.09% of its portfolio in the stock. Dimensional Fund Advsr Ltd Partnership accumulated 125,182 shares or 0% of the stock. Teacher Retirement Systems Of Texas last reported 0% of its portfolio in the stock. Gsa Prns Llp holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 11,298 shares. Moreover, Ra Cap Management Limited Liability Com has 13% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 12.03M shares. Diam Limited last reported 0.07% of its portfolio in the stock. American Century has 870,293 shares for 0.01% of their US portfolio. Janus Cap Limited Liability Company owns 5.71M shares or 0.04% of their US portfolio. Geode Capital Mngmt Lc last reported 880,254 shares in the company. Bourgeon Capital Mngmt Ltd Co accumulated 0.15% or 30,500 shares. Prudential Finance Inc accumulated 10,842 shares or 0% of the stock. Gotham Asset Mgmt Lc reported 191,792 shares or 0.02% of all its holdings. Blackrock Advsrs Ltd Liability Corp holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 183,836 shares. Manufacturers Life Insur Commerce The last reported 80,401 shares in the company.
ACHN Company Profile
Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.